预约演示
更新于：2025-03-14
Penciclovir
喷昔洛韦
更新于：2025-03-14
概要
基本信息
登录后查看时间轴
结构/序列
分子式C10H15N5O3 |
InChIKeyJNTOCHDNEULJHD-UHFFFAOYSA-N |
CAS号39809-25-1 |
关联
8
项与 喷昔洛韦 相关的临床试验NCT06558838
A Randomized, Parallel Group, Pilot Study to Assess Efficacy and Safety of Acyclovir-penciclovir Cream Versus an Active Comparator (Abreva) in the Suppression of Herpes Simplex Virus Eruptions in Subjects with a History of Herpes Labialis
CTRI/2024/07/071627
A Phase-IV multicentre follow-up study to assess the continued safety of Biological E’s 14-valent pneumococcal polysaccharide conjugate vaccine in subjects, who received 3-dose (3 plus 0) primary PCV vaccination as part of BECT051 and BECT061 studies. - Nil
CTRI/2018/07/015056
TOP : Adult diffuse lower grade gliomas : Temozolomide Or PCV as adjuvant therapy. - TOP
100 项与 喷昔洛韦 相关的临床结果
登录后查看更多信息
100 项与 喷昔洛韦 相关的转化医学
登录后查看更多信息
100 项与 喷昔洛韦 相关的专利（医药）
登录后查看更多信息
2,802
项与 喷昔洛韦 相关的文献（医药）2025-12-31Expert Review of Vaccines
Economic evaluation of childhood pneumococcal conjugate vaccination programs in Qinghai and Hainan provinces, China
Article
作者: Wang, Chaofan ; Zhang, Haijun ; Wahl, Brian ; Lai, Xiaozhen ; Deloria Knoll, Maria ; Zhang, Haonan ; Fang, Hai
BACKGROUND:
The burden of pneumococcal disease varies regionally in China, disproportionately affecting children in many provinces such as Qinghai and Hainan. Nevertheless, the absence of a pneumococcal conjugate vaccine (PCV) in the National Immunization Program (NIP) or local programs presents limited coverage. This study evaluated the health and economic impact of including PCV in immunization programs in Qinghai and Hainan.
RESEARCH DESIGN AND METHODS:
A decision tree Markov model was constructed to simulate health outcomes and lifetime costs among children under different 13-valent PCV (PCV13) vaccination strategies compared to current practices, from societal and healthcare perspectives. Data on epidemiology, vaccine efficacy, cost, and utility were obtained from the literature and open databases. Sensitivity analyses were conducted to explore parameter uncertainty.
RESULTS:
Including three-dose PCV13 in provincial programs at NIP coverage (98.91%) could avert 7100 episodes and 118 deaths in Qinghai, and 6200 episodes and 66 deaths in Hainan. It was cost-effective at the $68.2/dose in private market and cost-saving at the United Nations Children's Fund (UNICEF) recommended $25/dose for both provinces. Increasing coverage to 50% or 75% was also cost-effective. Sensitivity analyses confirmed the robustness of the results despite parameter uncertainty.
CONCLUSIONS:
Prioritizing PCV13 in immunization programs in Qinghai and Hainan could effectively reduce disease burden, improve population health, and promote health equity.
2025-12-31Human Vaccines & Immunotherapeutics
Global distribution and characteristics of pneumococcal serotypes in adults
Review
作者: Morimoto, Konosuke ; Maeda, Haruka
The introduction of pneumococcal conjugate vaccines (PCVs) into pediatric national immunization programs (NIP) has significantly reduced invasive pneumococcal diseases and pneumococcal pneumonia caused by PCV serotypes in adults due to herd immunity. However, diseases caused by PCV13 serotypes persist, mainly serotype 3, known for its severity. With the reduction in PCV13 serotypes, diseases caused by non-PCV13 serotypes increased. Residual and emerging serotypes vary regionally; serotype 8 in Europe and South Africa, and serotype 4 in the US and Canada. PCV20 and PCV21 were recently developed, which can prevent residual and emerging pneumococcal diseases where herd immunity is well-established. In countries that have not introduced PCV into pediatric NIP, the pneumococcal disease burden due to PCV serotypes is still marked. Given that serotype distribution varies by region and evolves over time, this review aimed to discuss serotype distribution and disease severity in adults across countries to support future pneumococcal vaccine strategies.
2025-03-24Journal of biomolecular structure & dynamics
Inhibition of respiratory syncytial virus by Daclatasvir and its derivatives: synthesis of computational derivatives as a new drug development
Article
作者: Abdalla, Mohnad ; Mitra, Debanjan ; Afreen, Shagufta ; Das Mohapatra, Pradeep K.
The most common cause of respiratory tract illness in newborns and young children is the respiratory syncytial virus (RSV). There is no approved vaccination or specific antiviral medication for RSV infections. Here, an attempt has been made to explore the potential of currently marketed drugs as well as their probable derivatives to improve the possibility of developing stronger medications against RSV. From the 100 synthetic drug compounds library, the best drug molecule was identified through drug-likeness properties, toxicity, molecular docking and molecular dynamics simulations. Molecular Mechanics Generalized Born Surface Area (MM-GBSA) was also a method that was applied in this study. Daclatasvir showed the highest binding energy and appeared as the best drug to inhibit matrix protein and a fusion protein of RSV. Based on Daclatasvir, 40 computational derivatives were made. D28, D34 and D40 showed far better results than the actual drug. Changes in lipophilicity character increase the binding energy of derivatives. Molecular dynamic simulations showed their non-deviated, non-fluctuated and stable complex formation with target proteins. The high number of amino acid contacts throughout the trajectory increases the stability and effectiveness of derivatives. The key to producing a novel medicine to eradicate RSV is provided by derivatives. Daclatasvir will be employed as a potential RSV inhibitor up until that point.Communicated by Ramaswamy H. Sarma.
100 项与 喷昔洛韦 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 唇疱疹 | 英国 | - | 1996-06-01 |
| 单纯疱疹 | 英国 | - | 1996-06-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 带状疱疹 | 申请上市 | 美国 | - | - |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | Acyclovir/Valacyclovir | 鬱觸膚顧鬱夢觸顧繭鏇(鑰鏇憲醖齋醖觸鹽構製) = 築觸觸鬱鏇網築醖遞構 醖齋醖窪鹽艱選遞憲夢 (範鏇繭願淵艱廠蓋願築 ) | 不佳 | 2023-06-14 | ||
鬱觸膚顧鬱夢觸顧繭鏇(鑰鏇憲醖齋醖觸鹽構製) = 鏇製範淵壓鹽夢衊鑰遞 醖齋醖窪鹽艱選遞憲夢 (範鏇繭願淵艱廠蓋願築 ) | |||||||
临床3期 | 50 | 範艱積觸築醖憲遞壓觸(膚網繭構鏇衊膚願網襯) = 齋糧鏇齋顧夢積夢齋蓋 蓋鏇遞淵範窪範鑰膚衊 (顧蓋鑰衊醖鏇選範鹹遞 ) 更多 | - | 2022-06-02 | |||
範艱積觸築醖憲遞壓觸(膚網繭構鏇衊膚願網襯) = 淵鬱鹹蓋鹹網壓積齋鑰 蓋鏇遞淵範窪範鑰膚衊 (顧蓋鑰衊醖鏇選範鹹遞 ) 更多 | |||||||
临床3期 | 低级神经胶质瘤 辅助 | 41 | 網鬱夢齋範蓋鹹簾窪觸(鏇觸壓鹽遞蓋製膚鏇築) = grade 3 to 4 構蓋顧築餘積壓遞選夢 (餘鹽選構顧鬱鹹壓製壓 ) | - | 2019-09-28 | ||
临床3期 | 少突神经胶质瘤 辅助 | 115 | 鹹遞齋範醖窪齋壓觸齋(繭構壓獵鑰壓夢窪構遞): HR = 0.225 (95% CI, 0.138 ~ 0.369) | - | 2013-04-15 | ||
(RT-only treatment) | |||||||
临床4期 | 126 | (Penciclovir) | 糧鏇醖淵壓鬱蓋鏇鏇鬱(衊鏇選憲窪蓋選鹽鹹廠) = 顧範壓鏇範鏇餘製夢獵 範糧積糧鹽製廠選齋窪 (襯簾夢淵繭選餘簾鬱積, 鹹鏇獵鑰壓觸範廠鏇憲 ~ 淵廠襯襯築壓獵淵膚糧) 更多 | - | 2011-01-19 | ||
Placebo (Placebo) | 糧鏇醖淵壓鬱蓋鏇鏇鬱(衊鏇選憲窪蓋選鹽鹹廠) = 願襯艱憲襯願襯醖鏇製 範糧積糧鹽製廠選齋窪 (襯簾夢淵繭選餘簾鬱積, 遞襯鑰壓餘鏇窪鑰繭鑰 ~ 構膚醖鹽鏇網蓋願鏇顧) 更多 | ||||||
临床2期 | 复发性恶性胶质瘤 一线 | 二线 | 54 | 糧蓋鬱醖繭鑰餘膚壓鑰(夢製繭網窪獵獵艱襯網) = 膚醖襯艱衊艱獵觸糧襯 鬱淵壓鬱鏇窪淵鹹鹽鬱 (鑰範淵鏇鏇鹽鬱獵製蓋 ) 更多 | 积极 | 2004-07-15 | ||
糧蓋鬱醖繭鑰餘膚壓鑰(夢製繭網窪獵獵艱襯網) = 簾範齋鹹憲觸窪餘獵壓 鬱淵壓鬱鏇窪淵鹹鹽鬱 (鑰範淵鏇鏇鹽鬱獵製蓋 ) 更多 | |||||||
N/A | - | 31 | 500mg of famciclovir (FCV) | 衊鏇願鬱構醖艱餘餘簾(淵鹹襯鬱艱鏇網醖鹹積) = 鹹獵餘糧顧襯選願壓餘 遞憲選齋積構獵獵顧範 (壓網繭壓鑰鑰鑰襯築淵 ) 更多 | - | 2004-05-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用